Purpose: To prevent the occurrence of secondary cataract after ECCE with PC-IOL implantation and evaluate the safety and effectiveness of Mitomycin C and 5-FU when used intraocular as an irrigating solution for its prevention in rabbits Materials and Methods: 15 rabbits were divided into 3 groups: Group A was given 5-50 mg/ml FU in 500 cc of BSS plus solution; Group B received MMC 0.2 percent mg/ml in 500 cc BSS; and Group C served as control with pure BSS. The study was done in accordance with the guidelines published by ARVO. The investigated drug solution was used as irrigating solution in cataract extraction performed in rabbits. Postoperatively, the rabbits examined under slit lamp from the 1st post op day and every 3 days thereafter. Their globes were enucleated 2 wks post op and 4 weeks post op, and sent to Pathology Laboratory for processing Results: Group A and Group B showed clear posterior capsule with no evidence of epithelial cell migration. Group C showed evidence of minimal to moderate epithelial cell migration and proliferation with fibrosis Conclusion: Mitomycin C (MMC) and 5-FU minimized and even prevented secondary cataract formation, with no effect on ocular structures when used as an irrigating solution.
Animal ; MITOMYCIN ; MITOMYCIN C ; MITOMYCINS

PURPOSE: The purpose of this study was to evaluate the effect of mitomycin C on rabbit keratocytes for their potential to modulate corneal stromal wound healing. We also investigated the pathway on which the modulation occurs. METHODS: Keratocytes were isolated from New Zealand White Rabbits and cultured. We used Hoechst stain and flowcytometric analysis with Annexin V to identify the kind of response that mitomycin C induced from the keratocytes. After cultured keratocytes were exposed to 0.005%, 0.01%, 0.02%, 0.04%, and 0.06% mitomycin C, we evaluated the response with LDH assay. Next, after exposing the keratocytes to 0.01% mitomycin C, we evaluated the responses with LDH assay at 6, 12, and 24 hours. Keratocytes were preincubated in various concentrations of CPP32-like protease inhibitor (Z-VAD-FMK(R)), specific caspase-8 inhibitor (Z-IETD-FMK(R)), and specific caspase-9 inhibitor (Z-LEHD-FMK(R)), then treated with 0.01% mitomycin C. Twelve hours later, an LDH assay was performed. Cytochrome C immunostain was done after exposure to 0.01% mitomycin C. RESULTS: We observed shrinkage of cytoplasm, formation of apoptotic bodies, and nuclear fragmentation on Hoechst staining. In flowcytometric analysis, the cells showed apoptotic change. LDH activities increased significantly at a concentration of 0.005% and greater and were time-dependent until 24 hours. CPP32-like protease inhibitor decreased the LDH activity, but there was no statistical significance. Specific caspase-8 and -9 inhibitors significantly reduced the LDH activities that were induced by mitomycin C. The keratocytes which had been pretreated with mitomycin C were stained with cytochrome C antibody. CONCLUSIONS: Mitomycin C induces apoptosis, rather than necrosis, in cultured corneal keratocytes. This apoptosis occurs via the caspase pathway, and is especially related to the mitochondrial pathway, and caspases 8, and 9.
Annexin A5 ; Apoptosis* ; Caspase 8 ; Caspase 9 ; Caspases ; Corneal Keratocytes ; Cytochromes c ; Cytoplasm ; Mitochondria ; Mitomycin* ; Necrosis ; Protease Inhibitors ; Rabbits ; Wound Healing

OBJECTIVETo investigate the role of p38MAPK and PI3K/AKT pathways in mitomycin (MMC)-induced apoptosis in the liver stem-like cell line WB-F344.

METHODSWB-F344 cells were exposed to MMC and apoptosis was evaluated by flow cytometry and DNA fragmentation. Phospho-MAPK and phospho-PI3K/AKT were detected by western blotting.

RESULTSMMC induced apoptosis in WB-F344 cells at 6h after addition of MMC; the maximum level of apoptosis was reached at 24h after MMC exposure. The apoptosis effects of MMC were concentration dependent and inhibited when the PI3K pathway was abolished by the specific inhibitor LY294002, but not inhibited when the p38MAPK pathway was abolished by inhibitor SB203508.

CONCLUSIONApoptosis of WB-F344 cells can be induced by MMC.Although MMC can activate both the PI3K/AKT and p38MAPK pathways, the apoptosis effect of MMC occurs via a PI3K pathway and is not dependent on the p38MAPK pathway.

Animals ; Apoptosis ; Blotting, Western ; Cell Line ; Chromones ; Flow Cytometry ; Mitomycin ; Morpholines ; Phosphatidylinositol 3-Kinases ; Proto-Oncogene Proteins c-akt ; Rats ; Signal Transduction ; p38 Mitogen-Activated Protein Kinases

OBJECTIVETo analyze the pharmacokinetics of intraperitoneal chemotherapy with mitomycin C (MMC) bound to activated carbon particles.

METHODSA nude mouse model with transplanted human gastric cancer was established. The mice were given MMC by i.v. or intraperitoneal (i.p.) injections, or given i.p. MMC bound to activated carbon particles (MMC-CH). Pharmacokinetic assays were carried out at different time points (0.5, 1, 2, 3, 6, 12 and 24 h) in 7 mice per each time point, to compare the MMC concentrations revealed by the above mentioned methods.

RESULTSThe MMC concentration in peritoneal exudate, omentum and lymph nodes of MMC-CH group was significantly higher than that of MMC solution i.p. group and MMC i.v. group (P < 0.001). On the other hand, the MMC level in serum was significantly lower than that in two control groups (P < 0.001). High MMC level was maintained longer than 24 hours in the MMC-CH group. Intraperitoneal chemotherapy with MMC solution resulted in a low MMC concentration in serum, peritoneal exudates and lymph nodes, and only a transient high level of MMC in the omentum. After i.v. administration, a significantly higher level of MMC concentration occurred in the serum, but only a shortly increased concentration of MMC in the omentum, and lower concentration in peritoneal exudate and lymph nodes as compared with those in the other two groups (P < 0.001).

CONCLUSIONHigh concentration of MMC in peritoneal exudate, omentum and lymph nodes maintained longer than 24 hours and a significantly lower MMC serum concentration can be achieved by administration of intraperitoneal administration of MMC bound to activated carbon particles.

Animals ; Antibiotics, Antineoplastic ; administration & dosage ; pharmacokinetics ; Charcoal ; administration & dosage ; pharmacokinetics ; Female ; Humans ; Injections, Intraperitoneal ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mitomycin ; administration & dosage ; pharmacokinetics ; Neoplasm Transplantation ; Stomach Neoplasms ; drug therapy ; metabolism ; pathology

Functional defects in mitochondria are involved in the induction of cell death in cancer cells. We assessed the toxic effect of camptothecin against the human cervical and uterine tumor cell line SiHa with respect to the mitochondria-mediated cell death process, and examined the combined effect of camptothecin and anticancer drugs. Camptothecin caused apoptosis in SiHa cells by inducing mitochondrial membrane permeability changes that lead to the loss of mitochondrial membrane potential, decreased Bcl-2 levels, cytochrome c release, caspase-3 activation, formation of reactive oxygen species and depletion of GSH. Combination of camptothecin with other anticancer drugs (carboplatin, paclitaxel, doxorubicin and mitomycin c) or signaling inhibitors (farnesyltransferase inhibitor and ERK inhibitor) did not enhance the camptothecin-induced cell death and caspase-3 activation. These results suggest that camptothecin may cause cell death in SiHa cells by inducing changes in mitochondrial membrane permeability, which leads to cytochrome c release and activation of caspase-3. This effect is also associated with increased formation of reactive oxygen species and depletion of GSH. Combination with other anticancer drugs (or signaling inhibitors) does not appear to increase the anti-tumor effect of camptothecin against SiHa cells, but rather may reduce it. Combination of camptothecin with other anticancer drugs does not seem to provide a benefit in the treatment of cervical and uterine cancer compared with camptothecin monotherapy.
Apoptosis ; Camptothecin ; Carcinoma, Squamous Cell ; Caspase 3 ; Cell Death ; Cell Line ; Cell Line, Tumor ; Cytochromes c ; Doxorubicin ; Humans ; Membrane Potential, Mitochondrial ; Mitochondria ; Mitochondrial Membranes ; Mitomycin ; Paclitaxel ; Permeability ; Reactive Oxygen Species ; Uterine Neoplasms

BACKGROUNDColorectal cancer (CRC) is a heterogeneous disease; current research relies on cancer cell lines and animal cancer models, which may not precisely imitate inner human tumors and guide clinical medicine. The purpose of our study was to explore and further improve the process of producing three-dimensional (3D) organoid model and impel the development of personalized therapy.

METHODSWe subcutaneously injected surgically resected CRC tissues from a patient into BALB/c-nu mice to build patient-derived xenografts (PDXs). Isolated cells from PDXs at appropriate tumor size were mingled with Matrigel, and then seeded in ultra-low attachment 96-well plates at four cell densities (500, 1000, 2000, and 4000 single cells/well). Cells were cultured with advanced Dulbecco's Modified Eagle Medium/F12 medium additional with various factors added to maintain tumor's biological traits and growth activity. The growth curves of the four cell densities were measured after 24 h of culture until 25 days. We evaluated the effects of four chemotherapeutic agents on organoid model by the CellTiter-Glo ® Luminescent Cell Viability Assay. Hematoxylin and eosin (H and E) staining of 3D organoids was performed and compared with patient and CRC PDX tissues. Furthermore, immunohistochemistry was performed, in which the organoids were stained with the proliferation marker, Ki-67. During the experimental process, a phase-contrast microscope was used.

RESULTSPhenotype experimental results showed that 3D organoids were tightly packed together and grew robustly over time. All four densities of cells formed organoids while that composed of 2000 cells/well provided an adequate cultivation system and grew approximately 8-fold at the 25 th day. The chemosensitivity of the four conventional drugs was [s]-10-hydroxycamptothecin > mitomycin C > adriamycin > paclitaxel, which can guide clinical treatment. Histological features of CRC patient's tumor tissues and mice tumor xenograft tissues were highly similar, with high-column-like epithelium and extracellular matrix. H and E-stained sections showed heterogeneous cell populations harbored in cancer organoids and were histologically similar to tumor tissues. The proliferation index was only 8.33% within spheroids, which exhibited confined proliferative cells that might be cancer stem cells.

CONCLUSIONSWe successfully constructed a CRC organoid model that grew robustly over 25 days and demonstrated that 2000 cells/well in 96-well plate was a prime seeding density for cells to form organoids. The results confirmed that organoid model can be used for agent screening and personalized medicine.

Adult ; Animals ; Antineoplastic Agents ; therapeutic use ; Cell Proliferation ; drug effects ; Cell Survival ; drug effects ; Colorectal Neoplasms ; drug therapy ; pathology ; Doxorubicin ; therapeutic use ; Humans ; Immunohistochemistry ; Male ; Mice ; Mice, Inbred BALB C ; Mitomycin ; therapeutic use ; Organoids ; drug effects ; pathology ; Paclitaxel ; therapeutic use ; Rectal Neoplasms ; drug therapy ; pathology ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays

OBJECTIVETo evaluate in vitro anti-tumor effect of chemotherapeutic drugs on human gastric cancer cells, and investigate the relationship with Bcl-2 expression.

METHODSSingle cell suspension was prepared from fresh gastric cancer tissue and exposed to taxol (Tax), 5-fluorouracil (5-FU), cisplatin (CDDP), adriamycin (ADM), mitomycin (MMC) respectively for 48 hours. Metabolic activity and inhibitory rate of cells were detected by MTT assay. Expression of Bcl-2 was examined with immunohistochemistry.

RESULTSThe inhibitory rates of cancer cells exposed to chemotherapeutic drugs were different and Tax, 5-FU, CDDP had remarkably higher rates than ADM and MMC. The lower differentiated gastric cancer cells were more sensitive than the higher ones. Positive expression rate of Bcl-2 was 80% and the positive cells showed resistance to 5-FU, ADM and MMC.

CONCLUSIONSChemosensitive testing by MTT assay can constitute the prediction for the application of chemotherapeutic drugs individually. Overexpression of Bcl-2 may contribute to multiple drug-resistance of tumors.

Adult ; Aged ; Antineoplastic Agents ; pharmacology ; therapeutic use ; Cell Survival ; Cisplatin ; pharmacology ; therapeutic use ; Doxorubicin ; pharmacology ; therapeutic use ; Drug Screening Assays, Antitumor ; Female ; Fluorouracil ; pharmacology ; therapeutic use ; Humans ; Male ; Middle Aged ; Mitomycin ; pharmacology ; therapeutic use ; Mitomycins ; pharmacology ; therapeutic use ; Paclitaxel ; pharmacology ; therapeutic use ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Stomach Neoplasms ; drug therapy ; metabolism ; pathology ; Tumor Cells, Cultured

AIMTo study the synergistic antitumor effect of sodium caffeate (sodium 3,4-dihydroxycinnamate, CA-Na) and mitomycin C (MMC).

METHODSMTT assay, Western Blotting analysis and flow cytometry were used to determine the effects of MMC alone and in combination with CA-Na on tumor cell proliferation, cell cycle progression and the expression of apoptosis-involved proteins Bcl-2 and caspase-3. Intracellular Ca2+ level and mitochondria membrane potential were also assayed. Inhibition of tumor growth was evaluated with hepatoma 22 transplanted s.c. in mice.

RESULTSSynergistic inhibition of hepatoma BEL-7402 cell proliferation was achieved by the combination of MMC and CA-Na. The combination of MMC and CA-Na caused more remarkable cell cycle perturbation in BEL-7402 cells than MMC alone. Combination of CA-Na and MMC synergistically inhibited Bcl-2 expression and enhanced caspase-3 expression of the cells. Intracellular Ca2+ level was significantly increased when the cells were treated with MMC combined with CA-Na. Mitochondria membrane potential was markedly decreased when treated with the combination. At doses of 0.5, 1.0 and 1.5 mg.kg-1, i.p., x 10, MMC inhibited the growth of hepatoma 22 by 35.9%, 62.7% and 79.1%, respectively. In combination with CA-Na, the inhibition rates of MMC increased to 62.4%, 70.5% and 88.0%, respectively.

CONCLUSIONThe combination of CA-Na and MMC showed synergistic effect against tumor cell proliferation in vitro and tumor growth in vivo.

Animals ; Antibiotics, Antineoplastic ; pharmacology ; Antineoplastic Agents ; pharmacology ; Caffeic Acids ; pharmacology ; Calcium ; metabolism ; Carcinoma, Hepatocellular ; metabolism ; pathology ; Caspase 3 ; Caspases ; metabolism ; Cell Division ; drug effects ; Drug Synergism ; Humans ; Liver Neoplasms ; metabolism ; pathology ; Mice ; Mitomycin ; pharmacology ; Neoplasm Transplantation ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Tumor Cells, Cultured

OBJECTIVETo prepare a new dosage formulation of activated carbon nanoparticles adsorbing mitomycin C (MMC-ACNP) and evaluate the beneficial effects of intraperitoneally applied MMC-ACNP as a drug delivery system for lymphatic targeting in preventing metastasis and recurrence of gastric cancer.

METHODSMMC-ACNP was prepared. Acute toxicity after its intraperitoneal administration was evaluated. An experiment on nude mice model with transplanted human gastric cancer in 6 groups was completed to assess the effects of drugs on intra-abdominal carcinomatosis.

RESULTSThe LD50 of MMC-ACNP was 46.80 mg/kg (in terms of MMC) while that of MMC aqueous solution was 9.33 mg/kg. The toxicity of MMC-ACNP was much less than that of the solution form. MMC-ACNP was superior to MMC aqueous solution in controlling carcinomatosis and tumor growth by intraperitoneal administration. Despite the high dose of MMC, leukopenia and thrombocytopenia were not observed in the MMC-ACNP treated group. Fine activated carbon particles adsorbing MMC entered the nuclei of tumor cells, so that the effects of the anticancer drug were reinforced.

CONCLUSIONMMC-ACNP gives a good promise of clinical use due to its advantages such as high selectivity and low toxicity.

Adenocarcinoma, Mucinous ; pathology ; Animals ; Antibiotics, Antineoplastic ; administration & dosage ; adverse effects ; pharmacology ; Charcoal ; administration & dosage ; Drug Carriers ; Drug Delivery Systems ; Female ; Humans ; Injections, Intraperitoneal ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mitomycin ; administration & dosage ; adverse effects ; pharmacology ; Nanoparticles ; Neoplasm Transplantation ; Stomach Neoplasms ; pathology ; Thrombocytopenia ; chemically induced

OBJECTIVETo evaluate the effect of combined use of oncolytic virus and the chemotherapeutic agents mitomycin (MMC) in growth inhibition of human bladder cancer cell line T-24 in vitro.

METHODSHuman bladder cancer cell line T-24 was infected with oncolytic virus (ONYX-015) of different multiplicity of infection, or treated with MMC in addition to ONYX-015. The changes in the cell growth, morphology, and apoptosis of cultured T-24 cells were observed by means of cell counting and fluorescence microscopy after the treatments. The effects of the treatment protocols were also tested in nude mouse model of implanted subcutaneous tumor.

RESULTSCombined use of ONYX-015 and MMC produced substantially stronger cytotoxic effect against T-24 cells than exclusive use of ONYX-015. In in vivo experiments, combination of oncolytic virus and MMC resulted in much more significant tumor growth inhibition than either of the agents used alone. Obvious T-24 cell apoptosis could be observed in response to combined ONYX-105 and MMC treatment and exclusive ONYX-105 treatment.

CONCLUSIONSONYX-015 combined with MMC can produce significant cytotoxicity against T-24 cells and enhance therapeutic efficacy against bladder carcinoma.

Animals ; Antibiotics, Antineoplastic ; pharmacology ; therapeutic use ; Apoptosis ; drug effects ; physiology ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Cell Survival ; drug effects ; Combined Modality Therapy ; Female ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mitomycin ; pharmacology ; therapeutic use ; Oncolytic Virotherapy ; methods ; Oncolytic Viruses ; physiology ; Urinary Bladder Neoplasms ; pathology ; therapy ; virology ; Xenograft Model Antitumor Assays